More Mini Brains

Simple versions of brain organoids could serve as new models for testing the effects of drugs, researchers reported at this year’s AAAS meeting.

Written byJef Akst
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

THOMAS HARTUNG/JOHNS HOPKINSMini brains, or orbs of neurons typically derived from human fibroblasts intended to better recapitulate human brain function than rodent models, just got simpler. At the annual meeting of the American Association for the Advancement of Science (AAAS) in Washington, DC, last week (February 12), Johns Hopkins University toxicologist Thomas Hartung described his group’s latest versions of these increasingly popular brain organoids, which have recently been used to study Down syndrome and autism, among other disorders, are only 350 micrometers in diameter—about the size of a housefly’s eye—yet contain multiple types of neurons, as well as astrocytes and oligodendrocytes.

The mini brains are smaller and more standardized than previous versions, Hartung said, comparing previous versions to Ferraris and Maseratis and his own to Mini Coopers, Science News reported. “We don’t have the first brain model nor are we claiming to have the best one,” Hartung said in a press release. “But this is the most standardized one. And when testing drugs, it is imperative that the cells being studied are as similar as possible to ensure the most comparable and accurate results.”

Hartung and colleagues now working to patent the mini brains and launch a company called Organome to produce them. The researchers hope to begin production this year. “Only when we can have brain models like this in any lab at any ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Jef (an unusual nickname for Jennifer) got her master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses. After four years of diving off the Gulf Coast of Tampa and performing behavioral experiments at the Tennessee Aquarium in Chattanooga, she left research to pursue a career in science writing. As The Scientist's managing editor, Jef edited features and oversaw the production of the TS Digest and quarterly print magazine. In 2022, her feature on uterus transplantation earned first place in the trade category of the Awards for Excellence in Health Care Journalism. She is a member of the National Association of Science Writers.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies